Duality Biotherapeutics Inc

Company Profile

• Business description

  Duality Biotherapeutics Inc is a key player in the antibody-drug conjugate (ADC) landscape, dedicated to the development of inventive therapeutics in this fast-growing drug modality to treat cancer, autoimmune diseases, and beyond. Its pipeline of 12 in-house discovered ADC candidates is a testament to its prowess in ADC innovation, comprising: (i) seven clinical-stage ADCs with potential in a broad range of indications, two next-generation bispecific ADCs, and multiple other preclinical ADCs. Its Products DB-1303/BNT323 and DB-1311/BNT324 and key product DB-1305/BNT325, have received Fast Track Designation. DB-1303 is a late clinical-stage HER2 ADC candidate with two ongoing registrational trials and one potential global registrational study.

• Contact

  No. 99 Jingu Road
  Unit 301, Building 3, Zone B, Suzhou Industrial Park
  Phase III, Biopharmaceutical Industrial Park
  Jiangsu Province
  Suzhou
  CHN

  https://www.dualitybiologics.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2025

  Employees

  170